Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov site revision identifier was updated to v3.8.1.SummaryDifference0.0%

- Check12 days agoChange DetectedThe page displays the completed phase 2 pembrolizumab study record, including its design, eligibility criteria, locations, outcomes, publications, and record dates.SummaryDifference77%

- Check19 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2. The page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA new NIH transition notice appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, replacing the previous detailed content. Sponsor-related materials and links to study documents have been removed.SummaryDifference18%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.